# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Arnold HOFFMAN, et al.

Appln. No.: Not Yet Assigned

Filed: July 18, 2003

For: REDOX THERAPY FOR TUMORS

Atty. Docket: HOFFMAN=9

Confirmation No.:

Art Unit: Not Yet Assigned

Examiner:

Washington, D.C.

### INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop DD Crystal Plaza Two, Lobby, Room 1803 Arlington, Virginia 22202

#### Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

#### (Check one of the boxes A-D)

[ ] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

- [X] B. before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.
- [ ] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "i" below).

(Check one of the boxes "i" and "ii" below:)

- [ ] i. Counsel certifies that, upon information and belief, each item of information listed herein was either
  - [ ] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
  - [ ] (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in \$1.56(c) more than three months prior to the filing of this IDS.

## (use one and delete other of following)

- [] ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in \$1.17(p), presently believed to be \$180. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035.
- [ ] D. after (A), (B) and (C) above, but before payment of the issue fee: Applicants state as follows under 37 CFR §1.97(e) for consideration of this IDS, that, upon

, In re Appln. No. Not Yet Assigned

information and belief, each item of information listed herein was either

(Check one of the boxes "a" and "b" below)

- [ ] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- [ ] (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in \$1.56(c) more than three months prior to the filing of this IDS.

Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in \$1.17(i), presently believed to be \$180 is enclosed. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A, B and/or C and fill in blanks, if appropriate)

[ ] A. Documents \_\_\_\_\_\_ are deemed substantially cumulative to documents \_\_\_\_\_\_, and, in accordance with §1.98(c), only a copy of each of the latter documents is enclosed.

• In re Appln. No. Not Yet Assigned [ ] B. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120: (insert serial numbers and filing dates of prior applications) Applicant(s) identifies these documents by attaching hereto copies of the forms PTO-892 and PTO-1449 (or PTO/SB/08A) from the files of the prior applications or a fresh PTO-1449 (or PTO/SB/08A) listing these documents, and request that they be considered and made of record in accordance with \$1.98(d). Per 37 CFR \$1.98(d), copies of these documents need not be filed in this application. [ ] C. Documents \_\_\_\_\_ are U.S. patents and/or published applications. As this is a U.S. application filed after June 30, 2003, or an entry into national stage under 35 USC §371 after June 30, 2003, the requirement to file copies of such U.S. patents or published applications has been waived. (Office of Patent Legal Administration - Pre O.G. Notice of July 11, 2003). 3. Documents \_\_\_\_\_ are not in the English language. In accordance with §1.98(c), Applicants state: [ ] An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed. [ ] A concise explanation of the relevance document(s) \_\_\_\_\_ is found in the attached search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

documents \_\_\_\_\_ is set forth as follows:

[ ] A concise explanation of the relevance

. In re Appln. No. Not Yet Assigned

(insert concise explanation of relevance)

- [ ] A concise explanation of the relevance of documents \_\_\_\_ can be found on pages \_\_\_ of the specification.
- [ ] A concise explanation of documents \_\_\_\_\_\_
  can be found on the attached sheet.
- 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 5. Other information being provided for the examiner's consideration follows:

(insert other information)

6. In accordance with 37 CFR §\$1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicants reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Roger L. Browdy

Reg. No. 25,618

RLB:zv

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197
Facsimile: (202)737-3528
G:\bn\b\bENA\hOFFMAN9\pTO\IDS210ct03.doc

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			· <del>=</del> ·-	Complete if Known	
				Application Number	Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)				Filing Date	July 18, 2003
				First Named Inventor	Arnold HOFFMAN, et al.
				Group Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	HOFFMAN=9

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>					
	BL	F. Q. SCHAFER et al;"Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple"; Free Rad Biol Med (2001); Vol. 30; pages 1191-212.						
Examir Signatu		Date Considered						

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.